ALVO on Nasdaq
Alvotech
Alvotech is a biological products company, listed on Nasdaq (ALVO).1
Price unavailable
Last updated Oct 21, 2026.
Overview
- TickerALVO on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersN41
- Incorporated inLuxembourg3
- Business address9, Rue De Bitbourg, Luxembourg, N4 L-12733
- Filer categoryLarge accelerated filer3
See how the biggest companies compare on our leaderboards
Alvotech hf. was founded in 2013 in Reykjavik, Iceland with the aim of creating a highly integrated platform company focused exclusively on developing and manufacturing biosimilars for the global market. Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Product and service revenue | $276.3M | $273.5M | $48.7M |
| License and other revenue | $310.1M | $216.2M | $42.7M |
| Other income | $2.6M | $2.3M | $1.9M |
| Cost of product and service revenue | -$235.6M | -$185.3M | -$160.9M |
| Research and development expenses | -$184.2M | -$171.3M | -$210.8M |
| General and administrative expenses | -$90.9M | -$65.7M | -$76.6M |
| Operating profit | $78.2M | $69.6M | -$354.9M |
| Share of net loss of joint venture | $0 | $0 | -$7.2M |
| Impairment loss on investment in joint venture | $0 | $0 | -$21.5M |
| Loss on sale of interest in joint venture | $0 | -$3.0M | $0 |
| Effects resulting from business combination | $8.0M | $0 | $0 |
| Finance income | $198.5M | $80.1M | $4.8M |
| Finance costs | -$149.2M | -$303.2M | -$267.2M |
| Exchange rate differences | -$16.8M | $8.2M | -$5.2M |
| Net gain / (loss) on modification and extinguishment of financial liabilities | $17.7M | -$69.4M | $0 |
| Non-operating profit / (loss) | $58.1M | -$287.2M | -$296.2M |
| Profit / (loss) before taxes | $136.3M | -$217.6M | -$651.0M |
| Income tax (expense) benefit | -$108.4M | -$14.3M | $99.3M |
| Profit / (loss) for the year | $27.9M | -$231.9M | -$551.7M |
| Exchange rate differences on translation of foreign operations | $3.6M | -$690.0K | -$86.0K |
| Total comprehensive profit / (loss) | $31.5M | -$232.6M | -$551.8M |
| Basic profit / (loss) for the period per share (in dollars per share) | $0.10 | -$0.87 | -$2.43 |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Property, plant and equipment | $356.4M | $284.5M | ||
| Right-of-use assets | $138.3M | $125.2M | $119.8M | |
| Goodwill | $12.8M | $11.3M | $12.1M | |
| Other intangible assets | $81.8M | $20.6M | ||
| Contract assets | $122.9M | $22.7M | ||
| Other long-term assets | $8.6M | $3.6M | ||
| Deferred tax assets | $192.2M | $298.4M | ||
| Total non-current assets | $913.1M | $766.4M | ||
| Inventories | $220.1M | $127.9M | ||
| Trade receivables | $69.7M | $160.2M | ||
| Contract assets | $64.4M | $67.3M | ||
| Other current assets | $47.0M | $48.1M | ||
| Receivables from related parties | $438.0K | $118.0K | ||
| Cash and cash equivalents | $172.4M | $51.4M | $11.2M | $66.4M |
| Total current assets | $574.0M | $455.0M | ||
| Total assets | $1.5B | $1.2B | ||
| Share capital | $2.9M | $2.8M | ||
| Share premium | $2.1B | $2.0B | ||
| Other reserves | $15.3M | $17.3M | ||
| Translation reserve | $1.4M | -$2.2M | ||
| Accumulated deficit | -$2.4B | -$2.4B | ||
| Total equity | -$284.5M | -$412.8M | -$932.5M | -$564.4M |
| Borrowings | $1.3B | $1.0B | ||
| Derivative financial liabilities | $54.0M | $210.2M | ||
| Lease liabilities | $138.0M | $112.1M | ||
| Contract liabilities | $5.5M | $80.7M | ||
| Deferred tax liability | $7.9M | $1.8M | ||
| Total non-current liabilities | $1.5B | $1.4B | ||
| Trade and other payables | $126.1M | $67.1M | ||
| Lease liabilities | $12.1M | $9.5M | ||
| Current maturities of borrowings | $36.9M | $32.7M | ||
| Liabilities to related parties | $3.3M | $8.5M | ||
| Contract liabilities | $30.4M | $16.0M | ||
| Taxes payable | $1.0M | $204.0K | ||
| Other current liabilities | $94.2M | $59.4M | ||
| Total current liabilities | $304.1M | $193.4M | ||
| Total liabilities | $1.8B | $1.6B | ||
| Total equity and liabilities | $1.5B | $1.2B |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Property, plant and equipment | $356.4M | $284.5M | ||
| Right-of-use assets | $138.3M | $125.2M | $119.8M | |
| Goodwill | $12.8M | $11.3M | $12.1M | |
| Other intangible assets | $81.8M | $20.6M | ||
| Contract assets | $122.9M | $22.7M | ||
| Other long-term assets | $8.6M | $3.6M | ||
| Deferred tax assets | $192.2M | $298.4M | ||
| Total non-current assets | $913.1M | $766.4M | ||
| Inventories | $220.1M | $127.9M | ||
| Trade receivables | $69.7M | $160.2M | ||
| Contract assets | $64.4M | $67.3M | ||
| Other current assets | $47.0M | $48.1M | ||
| Receivables from related parties | $438.0K | $118.0K | ||
| Cash and cash equivalents | $172.4M | $51.4M | $11.2M | $66.4M |
| Total current assets | $574.0M | $455.0M | ||
| Total assets | $1.5B | $1.2B | ||
| Share capital | $2.9M | $2.8M | ||
| Share premium | $2.1B | $2.0B | ||
| Other reserves | $15.3M | $17.3M | ||
| Translation reserve | $1.4M | -$2.2M | ||
| Accumulated deficit | -$2.4B | -$2.4B | ||
| Total equity | -$284.5M | -$412.8M | -$932.5M | -$564.4M |
| Borrowings | $1.3B | $1.0B | ||
| Derivative financial liabilities | $54.0M | $210.2M | ||
| Lease liabilities | $138.0M | $112.1M | ||
| Contract liabilities | $5.5M | $80.7M | ||
| Deferred tax liability | $7.9M | $1.8M | ||
| Total non-current liabilities | $1.5B | $1.4B | ||
| Trade and other payables | $126.1M | $67.1M | ||
| Lease liabilities | $12.1M | $9.5M | ||
| Current maturities of borrowings | $36.9M | $32.7M | ||
| Liabilities to related parties | $3.3M | $8.5M | ||
| Contract liabilities | $30.4M | $16.0M | ||
| Taxes payable | $1.0M | $204.0K | ||
| Other current liabilities | $94.2M | $59.4M | ||
| Total current liabilities | $304.1M | $193.4M | ||
| Total liabilities | $1.8B | $1.6B | ||
| Total equity and liabilities | $1.5B | $1.2B |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Profit / (loss) for the year | $27.9M | -$231.9M | -$551.7M |
| Long-term incentive plan expense | $0 | $0 | $78.0K |
| Depreciation, amortization and impairment | $37.9M | $31.3M | $24.2M |
| Impairment of other intangible assets | $0 | $0 | $1.8M |
| Impairment loss on investment in joint venture | $0 | $0 | $21.5M |
| Change in allowance for receivables | $703.0K | -$946.0K | $18.5M |
| Change in inventory reserves | $646.0K | -$3.5M | $8.3M |
| Share-based payments | $7.4M | $7.6M | $18.0M |
| Loss on disposal of property, plant and equipment | $0 | $0 | $365.0K |
| Effects resulting from business combination | -$8.0M | $0 | $0 |
| Loss on sale of interest in joint venture | $0 | $3.0M | $0 |
| Share of net loss of joint venture | $0 | $0 | $7.2M |
| Finance income | -$198.5M | -$80.1M | -$4.8M |
| Finance costs | $149.2M | $303.2M | $267.2M |
| Exchange rate difference | $16.8M | -$8.2M | $5.2M |
| Net (gain) / loss on modification and extinguishment of financial liabilities | -$17.7M | $69.4M | $0 |
| Income tax expense / (benefit) | $108.4M | $14.3M | -$99.3M |
| Operating cash flow before movement in working capital | $124.8M | $104.1M | -$283.6M |
| Increase in inventories | -$90.1M | -$50.0M | -$11.3M |
| Decrease / (increase) in trade receivables | $93.2M | -$119.1M | -$8.3M |
| (Decrease) increase in receivables with related parties | -$320.0K | $20.0K | $881.0K |
| Increase in contract assets | -$94.9M | -$45.2M | -$17.4M |
| Increase in other assets | -$4.2M | -$7.1M | -$802.0K |
| Increase / (decrease) in trade and other payables | $45.3M | -$13.7M | $31.8M |
| (Decrease) / increase in contract liabilities | -$69.3M | -$31.4M | $35.4M |
| (Decrease) / increase in liabilities with related parties | -$2.2M | -$7.9M | $1.3M |
| Increase / (decrease) in other liabilities | $5.1M | -$14.3M | -$5.2M |
| Cash from (used in) operations | $7.1M | -$184.5M | -$257.2M |
| Interest received | $2.4M | $4.6M | $3.6M |
| Interest paid | -$59.0M | -$54.9M | -$57.3M |
| Income tax paid | -$780.0K | -$2.0M | -$1.4M |
| Net cash used in operating activities | -$50.2M | -$236.8M | -$312.2M |
| Acquisition of property, plant and equipment | -$64.5M | -$53.7M | -$33.2M |
| Disposal of property, plant and equipment | $0 | $0 | $133.0K |
| Acquisition of intangible assets | -$31.7M | -$3.3M | -$13.2M |
| Restricted cash in connection with debt extinguishment | $0 | $26.1M | $0 |
| Net cash outflow on acquisition of subsidiary | -$14.0M | $0 | $0 |
| Proceeds from the sale in joint venture | $6.0M | $12.0M | $0 |
| Net used in investing activities | -$104.2M | -$18.9M | -$46.3M |
| Repayments of borrowings | -$25.4M | -$749.1M | -$99.4M |
| Repayments of principal portion of lease liabilities | -$10.4M | -$10.2M | -$8.3M |
| Proceeds from new borrowings | $233.5M | $896.3M | $278.8M |
| Transaction cost from new borrowings | -$5.6M | -$4.2M | -$9.0M |
| Gross proceeds from equity offering | $82.5M | $150.5M | $136.9M |
| Fees from equity offering | -$3.8M | -$5.8M | -$4.1M |
| Proceeds from warrants | $0 | $4.8M | $6.4M |
| Stock options exercised | $0 | $76.0K | $0 |
| Proceeds from loans from related parties | $0 | $24.5M | $0 |
| Repayment of loans from related parties | $0 | -$9.5M | $0 |
| Net cash generated from financing activities | $270.8M | $297.3M | $301.3M |
| (Decrease) increase in cash and cash equivalents | $116.4M | $41.6M | -$57.2M |
| Effect of movements in exchange rates on cash held | $4.5M | -$1.3M | $1.9M |
No quarter-by-quarter statement was filed.
Corporate structure
Alvotech sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Alvotech
- Celtic Holdings SCA Filed SCHEDULE 13D/A on Alvotech, latest Jun 30, 2026 (4 filings since Jun 27, 2022)
- Aztiq Pharma Partners S.a r.l. Filed SCHEDULE 13D/A on Alvotech, latest Mar 12, 2026 (4 filings since Jul 5, 2022)
- YA II PN, Ltd. Filed SC 13G/A on Alvotech, latest Nov 6, 2024 (2 filings since Jun 22, 2022)
- Oaktree Acquisition Holdings II, L.P. Filed SC 13G/A on Alvotech, latest Feb 14, 2024 (2 filings since Feb 14, 2023)
- Alvotech N4
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Alvotech reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, net | $356.4M2 Dec 31, 2025 | $284.5M2 Dec 31, 2024 | +25.3% |
| Operating-lease assets (leased space) | $138.3M2 Dec 31, 2025 | $125.2M2 Dec 31, 2024 | +10.5% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $172.4M2 Dec 31, 2025 | $51.4M2 Dec 31, 2024 | +235.1% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $12.8M2 Dec 31, 2025 | $11.3M2 Dec 31, 2024 | +13.3% |
| Intangible assets, net (excluding goodwill) | $81.8M2 Dec 31, 2025 | $20.6M2 Dec 31, 2024 | +296.8% |
Inventory
Former names
- Alvotech Lux Holdings S.A.S.Dec 20, 2021 to May 2, 20223
Calendar
Coming up
- Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.02) a share, on Nov 12, 2025.8
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
301 filings to the SEC since October 2021: 5 annual reports, 12 large holders, 284 other. The latest 20:
- Oct 14, 20266-K EDGAR
- Oct 7, 20266-K EDGAR
- Oct 5, 20266-K EDGAR
- Aug 31, 20266-K EDGAR
- Aug 21, 20266-K EDGAR
- Aug 19, 20266-K EDGAR
- Jul 29, 20266-K EDGAR
- Jul 1, 20266-K EDGAR
- Jun 30, 2026SCHEDULE 13D/A EDGAR
- Jun 18, 20266-K EDGAR
- Jun 17, 20266-K EDGAR
- Jun 16, 2026424B5 EDGAR
- Jun 16, 2026FWP EDGAR
- Jun 15, 2026FWP EDGAR
- Jun 15, 2026424B5 EDGAR
- Jun 15, 20266-K EDGAR
- Jun 8, 20266-K EDGAR
- Jun 4, 20266-K EDGAR
- May 11, 20266-K EDGAR
- May 4, 20266-K EDGAR
The 301 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Celtic Holdings SCASCHEDULE 13D/A, 4 filings Jun 27, 2022 to Jun 30, 20269
- Aztiq Pharma Partners S.a r.l.SCHEDULE 13D/A, 4 filings Jul 5, 2022 to Mar 12, 202610
- YA II PN, Ltd.SC 13G/A, 2 filings Jun 22, 2022 to Nov 6, 202411
- Oaktree Acquisition Holdings II, L.P.SC 13G/A, 2 filings Feb 14, 2023 to Feb 14, 202412
SEC filer profile
How Alvotech is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARAlvotech1
- CIK0001898416
- Employer ID (EIN)98-16293421
- Filer statusLarge accelerated filer not an emerging growth company; not a shell company4
- Incorporated inGrand Duchy of Luxembourg4
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address9, Rue De Bitbourg, Luxembourg, N4 L-12731
- Phone354 422-45001
- Shares outstanding312,021,375 shares as of Dec 31, 20254
- AuditorDeloitte ehf., Kópavogur, Iceland PCAOB ID 1490; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceDec 20, 20211
- Filings301 in all: 6-K (157), 424B3 (38), 425 (21), CORRESP (15), UPLOAD (13), EFFECT (8), F-4/A (6), 20-F (5)1
All 27 form types
SC 13D/A (4), 424B5 (3), 6-K/A (3), F-1/A (3), F-3 (3), F-1 (2), FWP (2), POS AM (2), SC 13D (2), SC 13G (2), SC 13G/A (2), SCHEDULE 13D/A (2), SEC STAFF LETTER (2), 8-A12B (1), CERT (1), F-3ASR (1), F-4 (1), RW (1), S-8 (1)
- Latest filingsAnnual report (20-F) Mar 31, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Ordinary Shares | ALVO | Nasdaq Stock Market LLC |
| Warrants | ALVOW | Nasdaq Stock Market LLC |
From the cover page of the 20-F filed Mar 31, 2026 (Section 12(b) of the Exchange Act).4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARAlvotech filings on SEC EDGAR
- 2SEC EDGARAlvotech 10-K for fiscal 2025
- 3SEC EDGARAlvotech filings on SEC EDGAR
- 4
- 5SEC EDGARAlvotech 10-K for fiscal 2020
- 6SEC EDGARAlvotech 10-K for fiscal 2021
- 7SEC EDGARAlvotech 10-K for fiscal 2022
- 8NasdaqNasdaq calendar
- 9
- 10
- 11SEC EDGARYA II PN, Ltd. SC 13G/A on Alvotech
- 12